ESRX - Express Scripts Holding Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.08
+0.28 (+0.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close76.80
Open76.67
Bid67.00 x 1400
Ask79.00 x 1100
Day's Range76.59 - 77.47
52 Week Range55.80 - 85.07
Volume1,181,427
Avg. Volume5,090,153
Market Cap43.297B
Beta1.08
PE Ratio (TTM)9.96
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2003-11-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • EARNINGS: Kohl's beats on profits, stock stuck in trading range
    Yahoo Finance Video4 days ago

    EARNINGS: Kohl's beats on profits, stock stuck in trading range

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the department store retailer announced first quarter earnings that beat on net income and revenue, as well as topping Wall Street estimates for comparable sales. UPDATE: Traders initially bought the news, but sold the stock after the CFO said on the earnings call that the second quarter faces "headwinds."

  • Qualcomm, Nike, Express Scripts & which sector to bet aga...
    CNBC Videos7 days ago

    Qualcomm, Nike, Express Scripts & which sector to bet aga...

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • EARNINGS: After Macy's blowout earnings, traders on alert for a bull trap
    Yahoo Finance Video10 days ago

    EARNINGS: After Macy's blowout earnings, traders on alert for a bull trap

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Macy's reported first quarter 2018 earnings, which beat Wall Street expectations on profit and revenue, and also raised full year guidance.

  • Forbes3 days ago

    New Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little Value

    Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.

  • Reuters3 days ago

    Lawsuit against Express Scripts over Anthem ties dismissed

    A federal judge on Tuesday dismissed a lawsuit brought against Express Scripts Holding Co by shareholders who accused the pharmacy benefits manager of inflating its share price by hiding its deteriorating relationship with its largest customer, Anthem Inc. U.S. District Judge Edgardo Ramos in Manhattan, who dismissed an earlier version of the lawsuit last August, said shareholders failed to support their claim that Express Scripts knowingly misled them. Unlike last year, Ramos did not leave the shareholders permission to file a new version of their case.

  • InvestorPlace7 days ago

    Sell CVS Health Corp and Express Scripts Holding Company as Trump Readies Attack

    Signs abound that the Trump administration plans to take tough action against pharmacy benefit managers, or PBMs, including CVS Health Corp (NYSE:CVS) and Express Scripts Holding Company (NASDAQ:ESRX), in order to lower the price of prescription drugs. Consequently, investors should sell CVS stock and Express Scripts stock. The clearest sign of the impending fate of the PBMs is that President Trump himself said that the administration was “very much eliminating” the prescription drug “middlemen.” Trump added that “The middlemen became very, very rich.

  • Reuters8 days ago

    U.S. FDA approves Amgen drug for prevention of migraines

    Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, Amgen spokeswoman Kristen Davis said.

  • Express Scripts to remain in St. Louis County, filing says
    American City Business Journals9 days ago

    Express Scripts to remain in St. Louis County, filing says

    Four of Express Scripts' current board members will serve on the combined company's board.

  • Moody’s likes the upward financial trend at this Lakeland pharmacy benefits manager
    American City Business Journals9 days ago

    Moody’s likes the upward financial trend at this Lakeland pharmacy benefits manager

    The credit agency still has concerns about the company’s high debt levels.

  • Barrons.com10 days ago

    ValueAct Dumps Microsoft, Express Scripts

    ValueAct now holds 16.2 million Citigroup shares. In other major first-quarter moves, ValueAct exited its positions in Microsoft (MSFT) and pharmacy benefit manager Express Scripts (ESRX). Perhaps the writing was on the wall about Microsoft.

  • Here's what the biggest hedge funds have been buying and selling
    Yahoo Finance10 days ago

    Here's what the biggest hedge funds have been buying and selling

    Facebook makes friends, while Apple gets dropped by some.

  • Reuters11 days ago

    U.S. to consider expanding Medicare drug price negotiation

    WASHINGTON/NEW YORK, May 14 (Reuters) - The Trump administration is considering expanding Medicare's ability to negotiate the cost of drugs by giving private payers a role in setting the price of medicines administered in hospitals and doctors' offices, Health and Human Services Secretary Alex Azar said on Monday. Azar's comments provided more details on the plan to lower prescription drug costs for Americans announced on Friday by President Donald Trump. While Trump assailed "middlemen," an apparent reference to health insurers and pharmacy benefit managers (PBMs), for pocketing negotiated rebates on drugs rather than passing savings to consumers, the proposal discussed on Monday appears to see them as part of the solution to high prices.

  • The Wall Street Journal14 days ago

    [$$] Reckoning for Drug Middlemen Is Postponed, Not Canceled

    Healthcare investors who were on the edges of their seats on Friday afternoon were relieved. Share prices of potentially-affected “middlemen” such as pharmacy-benefit managers, and to a lesser extent health insurers, fell sharply but then rebounded within minutes in late trading. After all, Mr. Trump’s comments were characteristically vague and didn’t unveil any immediate action to cut drug spending that might harm the profitability of companies like Express Scripts Holding or CVS Health.

  • The Wall Street Journal14 days ago

    [$$] Trump’s Plan to Cut Drug Prices Leaves Industry Relieved

    WASHINGTON—President Donald Trump unveiled dozens of initiatives aimed at curbing high drug prices Friday, a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks. “We’re going to take on one of the biggest obstacles to affordable medicine: the tangled web of special interests,” Mr. Trump said from the White House Rose Garden.

  • Barrons.com14 days ago

    Trump Trashes Pharma's Middlemen, but the Stocks Rise

    President Donald Trump this afternoon unveiled his plan to crack down on high-priced drugs. Pharmaceutical industry investors were unfazed. In fact, the stocks of the firms he hit hardest—the "middlemen" known as pharmacy-benefit managers—jumped as traders saw little in the administration's program that could hurt PBM outfits like Express Scripts Holding (ESRX) and CVS Health (CVS), the parent of the benefit business Caremark.

  • Trump assails high drug prices, avoids direct hit on industry
    Reuters14 days ago

    Trump assails high drug prices, avoids direct hit on industry

    U.S. President Donald Trump on Friday blasted drugmakers and healthcare "middlemen" for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices. Trump made the remarks at the White House Rose Garden in a speech to introduce what he called "the most sweeping action in history" to lower drug prices. Trump said his administration would take aim at the "middlemen" in the drug industry who became "very, very rich," an apparent reference to health insurers and pharmacy benefit managers (PBMs).

  • Reuters14 days ago

    Trump assails high drug prices, avoids direct hit on industry

    U.S. President Donald Trump on Friday blasted drugmakers and healthcare "middlemen" for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices. Trump made the remarks at the White House Rose Garden in a speech to introduce what he called "the most sweeping action in history" to lower drug prices. Trump said his administration would take aim at the "middlemen" in the drug industry who became "very, very rich," an apparent reference to health insurers and pharmacy benefit managers (PBMs).

  • TheStreet.com14 days ago

    Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

    President Trump delivered a highly-anticipated speech on lowering the cost of drugs for Americans on Friday afternoon.

  • Forbes14 days ago

    Trump Doesn't Know Who 'Middlemen' Are, But PBMs Okay With His Drug Price Agenda

    Alex Azar, secretary of Health and Human Services, speaks as Donald Trump listens during an event on lowering drug prices outside the White House in Washington, D.C., U.S., on Friday, May 11, 2018. “We're very much eliminating the middlemen,” Trump said of his administration’s proposed “American Patients First” blueprint to lower prices.

  • Benzinga14 days ago

    Trump Strikes At PBMs, Insurers, Drugmakers With Plans To Lower Consumer Prices

    Stocks representing the U.S. drug supply chain temporarily tumbled Friday as President Donald Trump proposed a broad plan to lower consumer health costs. Last year, it increased federal lobbying spending by 30 percent, and it may maintain such investments to prevent future follow-through.

  • CNBC14 days ago

    Trump: We're taking on the tangled web of special interests to lower drug prices

    President Donald Trump unveiled his administration's plan to lower drug prices. Health and Human Services Secretary Alex Azar told CNBC on Friday everyone's benefiting from high drug prices except patients and taxpayers. President Donald Trump criticized middlemen in a speech introducing his plan to lower prescription drug prices, but the proposals his administration unveiled largely spared health-care companies massive reforms.

  • CNBC14 days ago

    Health-care stocks whipsaw as Trump unveils plan to lower prescription drug prices

    Health care stocks whipsawed on Friday as President Donald Trump unveiled his long-awaited plan to lower prescription drug prices, dubbed "American Patients First."

  • InvestorPlace15 days ago

    Even After Earnings Beat, Cigna Corporation Stock Still Looks Stuck

    Five months in, 2018 has not been kind to Cigna Corporation (NYSE:CI) stock. A strong run in which CI stock doubled between the November 2016 election and late January reversed quickly. CI stock now is off some 25% from its all-time highs reached a little over three months ago — and down more than 15% so far this year while the broader S&P 500 Index is up a hair above 1%.

  • InvestorPlace15 days ago

    Earnings Show CVS Health Corp on Track To Benefit From Transformation

    CVS Health Corp (NYSE:CVS) reported Q1 earnings, the shares are back to where they started, despite a bit of a roller-coaster ride. The Woonsocket, Rhode Island-based healthcare services company beat earnings estimates but missed on revenue. With its pending acquisition of Aetna, CVS starts a new chapter (maybe a whole book).

  • CNBC15 days ago

    Trump plan won't allow Medicare to negotiate prices but will propose some drug plans share discounts

    President Donald Trump will unveil a plan to lower drug prices. President Donald Trump will unveil a plan to limit prices on some costly drugs, though it will not go as far as some Democrats want, according to senior administration officials. The plan, set to be released Friday, will require Medicare Part D plans share a portion of discounts they receive from drug manufacturers with patients, the officials said.